RSLV-132

RSLV-132 is a fully human recombinant fusion protein composed of catalytically active human ribonuclease 1 (RNase1) fused to the Fc portion of human IgG1. It is designed to remain in circulation and digest extracellular RNA, thereby reducing chronic inflammation associated with autoimmune diseases. The drug targets pathogenic cell-free RNA, which can trigger type I interferon release and drive inflammatory processes in conditions such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, and post-acute sequelae of SARS-CoV-2 infection (PASC). By degrading extracellular RNA, RSLV-132 acts as a B cell inhibitor, interferon alpha inhibitor, and ribonuclease stimulant. It has demonstrated an excellent safety profile in multiple phase 2 trials and is non-immunosuppressive[1][3][4][5][7].